Close Menu

NEW YORK – Biocept and Aegea Biotechnologies said Thursday that they have signed an agreement under which they will codevelop a PCR-based COVID-19 assay using the Switch-Blocker technology co-owned by the two firms. 

Switch-Blocker is currently the core of Biocept's suite of blood-based assays for cancer mutation detection. The underlying intellectual property is jointly owned by Biocept and Aegea, with Aegea holding exclusive rights in the field of infectious disease, and Biocept has certain rights within the field of clinical oncology.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.